Effect of Immune Rosettes on Cellularity of Leukapheresis Obtained From Normal Donors, T- or B-Precursor Acute Lymphoblastic Leukemia (ALL), B-Non-Hodgkins' Lymphoma (B-NHL) and Multiple Myeloma (MM) Patients
| Antibody Used . | Normal Donors (n = 18) . | T-ALL (n = 10) . | B-NHL, B-Precursor ALL and MM (n = 16) . | |||
|---|---|---|---|---|---|---|
| Apheresis (—) . | Immune Rosettes (CD11b + CD6) . | Apheresis (—) . | Immune Rosettes (CD11b + CD6) . | Apheresis (—) . | Immune Rosettes (CD11b) . | |
| Total cells (×109) | 41.3 (29.7-58.2) | 3.9 (1-13.7) | 28 (12.7-53.4) | 3.4 (0.4-8) | 20 (11.6-41.4) | 2.3 (1.1-4.4) |
| % overall cell loss | 91 (72-97) | 88 (77-97) | 87 (75-97) | |||
| CD34+ cells (×109) | 0.2 (0.07-1) | 0.2 (0.06-0.7) | 0.3 (0.09-0.8) | 0.2 (0.06-0.6) | 0.3 (0.1-1.3) | 0.3 (0.08-1) |
| %CD34+ cells | 0.6 (0.2-1.8) | 7.5 (2.3-22.4) | 1.2 (0.4-2.8) | 10 (4-21) | 1.9 (0.6-5.4) | 14 (2-28) |
| %CD34 recovery | 92 (67-100) | 89 (64-100) | 87 (65-100) | |||
| %CD34 enrichment fold | 15 (3-41) | 11 (4-21) | 10 (3-35) | |||
| CD11b+ cells (×109) | 25.5 (15.4-36) | 1.8 (0.01-10.8) | 21 (7.9-50.6) | 1.9 (0.1-6.3) | 16.2 (5.5-39.6) | 0.5 (0.01-1.2) |
| %CD11b+ cells | 63 (44-79) | 31 (1-83) | 70 (50-95) | 49 (16-83) | 77 (39-98) | 20 (0.6-38) |
| %CD11b+ cell loss | 93 (67-99) | 92 (73-98) | 96 (83-99) | |||
| CD3+ cells (×109) | 12.7 (7-27) | 0.9 (0.1-2.7) | 5.9 (0.6-14.3) | 0.8 (0.1-2.8) | 2.7 (0.5-7.9) | 1.3 (0.3-3) |
| %CD3+ cells | 30 (17-64) | 28 (6-62) | 29 (1-56) | 27 (3-63) | 17 (1.4-47) | 53 (15-90) |
| %CD3+ cell loss | 91 (70-99) | 84 (68-98) | 48 (11-63) | |||
| CD19+ cells (×109) | 2.2 (1-5) | 0.6 (0.08-1.2) | 0.09 (0.03-0.2) | 0.02 (0.002-0.07) | 0.06 (0-0.2) | 0.01 (0-0.05) |
| %CD19+ cells | 5 (2-12) | 22 (3-50) | 0.4 (0.1-1.4) | 0.8 (0.1-3) | 0.3 (0-1.2) | 0.5 (0-1.8) |
| %CD19+ cell loss | 71 (38-96) | 76 (38-98) | 74 (2-97) | |||
| Antibody Used . | Normal Donors (n = 18) . | T-ALL (n = 10) . | B-NHL, B-Precursor ALL and MM (n = 16) . | |||
|---|---|---|---|---|---|---|
| Apheresis (—) . | Immune Rosettes (CD11b + CD6) . | Apheresis (—) . | Immune Rosettes (CD11b + CD6) . | Apheresis (—) . | Immune Rosettes (CD11b) . | |
| Total cells (×109) | 41.3 (29.7-58.2) | 3.9 (1-13.7) | 28 (12.7-53.4) | 3.4 (0.4-8) | 20 (11.6-41.4) | 2.3 (1.1-4.4) |
| % overall cell loss | 91 (72-97) | 88 (77-97) | 87 (75-97) | |||
| CD34+ cells (×109) | 0.2 (0.07-1) | 0.2 (0.06-0.7) | 0.3 (0.09-0.8) | 0.2 (0.06-0.6) | 0.3 (0.1-1.3) | 0.3 (0.08-1) |
| %CD34+ cells | 0.6 (0.2-1.8) | 7.5 (2.3-22.4) | 1.2 (0.4-2.8) | 10 (4-21) | 1.9 (0.6-5.4) | 14 (2-28) |
| %CD34 recovery | 92 (67-100) | 89 (64-100) | 87 (65-100) | |||
| %CD34 enrichment fold | 15 (3-41) | 11 (4-21) | 10 (3-35) | |||
| CD11b+ cells (×109) | 25.5 (15.4-36) | 1.8 (0.01-10.8) | 21 (7.9-50.6) | 1.9 (0.1-6.3) | 16.2 (5.5-39.6) | 0.5 (0.01-1.2) |
| %CD11b+ cells | 63 (44-79) | 31 (1-83) | 70 (50-95) | 49 (16-83) | 77 (39-98) | 20 (0.6-38) |
| %CD11b+ cell loss | 93 (67-99) | 92 (73-98) | 96 (83-99) | |||
| CD3+ cells (×109) | 12.7 (7-27) | 0.9 (0.1-2.7) | 5.9 (0.6-14.3) | 0.8 (0.1-2.8) | 2.7 (0.5-7.9) | 1.3 (0.3-3) |
| %CD3+ cells | 30 (17-64) | 28 (6-62) | 29 (1-56) | 27 (3-63) | 17 (1.4-47) | 53 (15-90) |
| %CD3+ cell loss | 91 (70-99) | 84 (68-98) | 48 (11-63) | |||
| CD19+ cells (×109) | 2.2 (1-5) | 0.6 (0.08-1.2) | 0.09 (0.03-0.2) | 0.02 (0.002-0.07) | 0.06 (0-0.2) | 0.01 (0-0.05) |
| %CD19+ cells | 5 (2-12) | 22 (3-50) | 0.4 (0.1-1.4) | 0.8 (0.1-3) | 0.3 (0-1.2) | 0.5 (0-1.8) |
| %CD19+ cell loss | 71 (38-96) | 76 (38-98) | 74 (2-97) | |||